iShares Neuroscience and Healthcare ETF Rating $21.46 -0.89 (-3.98%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock iShares Neuroscience and Healthcare ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IBRN Aggregate RatingModerate Buy 2.76Holdings in IBRN have an aggregate rating of Moderate Buy based on 406 analyst ratings issued in the past year covering 43 companies (84.4% of the portfolio).IBRN Aggregate Price Target$21.46High Prediction$21.46Average Prediction$21.46Low Prediction$21.46Holdings in IBRN have an aggregate price target of $21.46 and a range of $21.46 to $21.46 covering 43 companies (84.4% of the portfolio).IBRN Consensus Ratings of HoldingsStrong Buy1 Strong Buy rating(s)Buy23 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Neuroscience and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 43 IBRN Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.00%ITCIIntra-Cellular Therapies$131.870.0%3.5775 of 5 stars2.47$106.08 -19.6%15News CoveragePositive NewsHigh Trading Volume5.30%PTCTPTC Therapeutics$46.60-8.6%3.8813 of 5 stars2.53$63.77 36.8%15Analyst ForecastHigh Trading Volume4.85%ALKSAlkermes$32.53-1.5%4.6088 of 5 stars2.69$39.38 21.1%13Positive News4.73%CPRXCatalyst Pharmaceuticals$23.92-1.4%4.8252 of 5 stars3.13$32.29 35.0%84.47%ACADACADIA Pharmaceuticals$16.32-1.7%4.1521 of 5 stars2.50$23.93 46.7%16Gap Up4.43%ARGXargenx$567.09-4.2%3.1242 of 5 stars2.91$687.00 21.1%23Positive News4.03%BIIBBiogen$132.03-3.5%4.8745 of 5 stars2.43$213.33 61.6%30News CoveragePositive News3.91%SUPNSupernus Pharmaceuticals$31.68-3.3%2.77 of 5 stars2.33$36.00 13.6%3Short Interest ↓3.86%NBIXNeurocrine Biosciences$107.00-3.3%4.9203 of 5 stars2.83$165.38 54.6%23Positive News3.70%IARTIntegra LifeSciences$21.61-1.7%2.6255 of 5 stars1.89$23.00 6.4%9Analyst UpgradeNews CoveragePositive News3.67%XENEXenon Pharmaceuticals$30.64-8.7%2.4225 of 5 stars3.00$57.38 87.3%9Analyst UpgradeNews CoveragePositive NewsHigh Trading Volume3.47%SRRKScholar Rock$30.06-6.5%4.095 of 5 stars3.00$42.67 41.9%63.29%EWTXEdgewise Therapeutics$20.13-8.5%1.9373 of 5 stars2.88$45.38 125.4%82.83%BHVNBiohaven$22.60-6.0%3.9572 of 5 stars3.07$62.77 177.8%152.58%SRPTSarepta Therapeutics$61.91-3.0%4.8344 of 5 stars2.78$164.05 165.0%23Analyst DowngradeNews CoverageHigh Trading Volume2.01%AVXLAnavex Life Sciences$8.02-6.5%3.7877 of 5 stars3.33$44.00 448.6%3Analyst ForecastNews Coverage1.88%AVDLAvadel Pharmaceuticals$7.51-4.1%3.3108 of 5 stars3.00$19.88 164.6%8Positive News1.87%DYNDyne Therapeutics$9.23-11.8%2.8831 of 5 stars3.07$47.46 414.2%15High Trading Volume1.84%AXGNAxoGen$17.81-3.7%3.5206 of 5 stars3.00$22.60 26.9%5Short Interest ↓1.60%PRAXPraxis Precision Medicines$35.87-5.3%2.1296 of 5 stars2.78$123.33 243.8%9High Trading Volume1.42%PRTAProthena$11.74-5.2%3.2772 of 5 stars2.75$55.00 368.5%8News CoveragePositive News1.41%CAPRCapricor Therapeutics$9.48-0.1%2.0161 of 5 stars3.00$34.50 263.9%61.05%ZVRAZevra Therapeutics$7.32-2.3%2.9642 of 5 stars3.11$22.29 204.4%90.96%DNTHDianthus Therapeutics$16.83-7.2%1.36 of 5 stars3.22$54.33 222.8%90.80%CLPTClearPoint Neuro$13.09+10.1%2.3385 of 5 stars3.00$25.00 91.0%3Analyst ForecastNews CoverageGap Up0.67%VNDAVanda Pharmaceuticals$4.50-2.0%4.2803 of 5 stars3.00$16.50 266.7%2Analyst ForecastNews Coverage0.64%TSHATaysha Gene Therapies$1.27-9.0%2.7322 of 5 stars3.00$6.63 423.7%8News CoveragePositive NewsGap Up0.61%NGNENeurogene$9.65-17.6%2.303 of 5 stars3.13$59.80 519.7%8High Trading Volume0.56%TRDAEntrada Therapeutics$8.76-3.1%2.7591 of 5 stars3.25$25.67 193.0%4Analyst Forecast0.55%ANNXAnnexon$1.81-6.2%2.2378 of 5 stars3.00$18.67 931.3%4Positive News0.50%ABEOAbeona Therapeutics$4.45-6.5%4.2127 of 5 stars3.00$17.50 293.3%4Insider TradeHigh Trading Volume0.50%NVRONevro$5.85+0.1%0.9147 of 5 stars1.92$6.43 9.9%13Analyst Forecast0.43%RAPPRapport Therapeutics$9.56-4.7%1.7433 of 5 stars3.00$35.00 266.1%3Short Interest ↑0.43%VYGRVoyager Therapeutics$3.37-0.3%4.5355 of 5 stars3.11$13.97 314.4%90.41%SGMOSangamo Therapeutics$0.57-13.1%1.7433 of 5 stars2.67$5.17 806.3%6Gap Up0.40%AMLXAmylyx Pharmaceuticals$3.34-5.6%2.8397 of 5 stars2.71$7.33 119.6%70.38%SLDBSolid Biosciences$3.44-7.0%3.3754 of 5 stars3.33$15.67 355.4%12Positive NewsHigh Trading Volume0.28%SAVACassava Sciences$1.38-8.0%3.8765 of 5 stars2.50$54.50 3,849.3%2Short Interest ↓0.25%CTNMContineum Therapeutics$6.46-7.4%2.1465 of 5 stars3.17$24.80 283.9%60.24%ALECAlector$1.16-5.7%3.8113 of 5 stars2.14$3.50 201.7%70.23%LRMRLarimar Therapeutics$2.00-7.0%1.9414 of 5 stars3.08$20.22 911.1%120.16%CLYMClimb Bio$1.20-1.6%3.0107 of 5 stars3.50$10.00 733.3%2Earnings Report0.15%ANROAlto Neuroscience$2.03-6.3%1.5854 of 5 stars2.50$16.75 727.2%6 This page (NYSEARCA:IBRN) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Neuroscience and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Neuroscience and Healthcare ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IBRN Stock Free IBRN Stock Alerts